{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T16:37:11Z","timestamp":1774543031198,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,7,18]],"date-time":"2011-07-18T00:00:00Z","timestamp":1310947200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Endovascular treatment options for the superficial femoral artery are evolving rapidly. For long lesions, the venous femoropopliteal bypass considered to be superior above the prosthetic bypass. An endoluminal bypass, however, may provide equal patency rates compared to the prosthetic above knee bypass. The introduction of heparin-bonded endografts may further improve patency rates. The SUrgical versus PERcutaneous Bypass (SuperB) study is designed to assess whether a heparin-bonded endoluminal bypass provides equal patency rates compared to the venous bypass and to prove that it is associated with improved quality of life, related to a decreased complication rate, or not.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\/design<\/jats:title>\n            <jats:p>Two-hundred-twenty-two patients with peripheral arterial occlusive disease, category 3-6 according to Rutherford, will be randomized in two treatment arms; 1. the surgical femoro-popliteal bypass, venous whenever possible, and 2. the heparin-bonded endoluminal bypass. The power analysis was based on a non-inferiority principle, with an effect size of 90% and 10% margins (alpha 5%, power 80%). Patients will be recruited from 5 teaching hospitals in the Netherlands during a 2-year period. The primary endpoint is primary patency and quality of life evaluated by the RAND-36 questionnaire and the Walking Impairment Questionnaire. Secondary endpoints include secondary patency, freedom-from-TLR and complications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>The SuperB trial is a multicentre randomized controlled trial designed to show non-inferiority in patency rates of the heparin-bonded endograft compared to the surgical bypass for treatment of long SFA lesions, and to prove a better quality of life using the heparin bonded-endograft compared to surgically treatment, related to a reduction in complications.<\/jats:p>\n            <jats:p>Trial Registration<\/jats:p>\n            <jats:p>Clinicaltrials: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01220245\" ext-link-type=\"uri\">NCT01220245<\/jats:ext-link>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1745-6215-12-178","type":"journal-article","created":{"date-parts":[[2011,8,17]],"date-time":"2011-08-17T18:17:08Z","timestamp":1313605028000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["SUrgical versus PERcutaneous Bypass: SUPERB-trial; Heparin-bonded endoluminal versus surgical femoro-popliteal bypass: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"12","author":[{"given":"Mare MA","family":"Lensvelt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Holewijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert M","family":"Fritschy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otmar RM","family":"Wikkeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurens A","family":"van Walraven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bas M","family":"Wallis de Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clark J","family":"Zeebregts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel MPJ","family":"Reijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,7,18]]},"reference":[{"key":"710_CR1","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ejvs.2003.12.027","volume":"27","author":"P Klinkert","year":"2004","unstructured":"Klinkert P, Post PN, Breslau PJ, van Bockel JH: Saphenous vein versus PTFE for above-knee femoro-popliteal bypass. A review of the literature. Eur J Vasc Endovasc Surg. 2004, 27: 357-62. 10.1016\/j.ejvs.2003.12.027.","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"710_CR2","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1016\/S0140-6736(05)67704-5","volume":"366","author":"DJ Adam","year":"2005","unstructured":"Adam DJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, Fowkes FG, Gillepsie I, Ruckley CV, Raab G, Storkey H, BASIL trial participants: Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial. Lancet. 2005, 366: 1925-34.","journal-title":"Lancet"},{"issue":"2 Suppl 2","key":"710_CR3","first-page":"II82","volume":"16","author":"GM Ansel","year":"2009","unstructured":"Ansel GM, Lumsden AB: Evolving modalities for femoro-popliteal interventions. J Endovasc Ther. 2009, 16 (2 Suppl 2): II82-II97.","journal-title":"J Endovasc Ther"},{"key":"710_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1053\/j.tvir.2009.10.005","volume":"13","author":"JM Gibbs","year":"2010","unstructured":"Gibbs JM, Pena CS, Benenati JF: Treating the diseased superficial femoral artery. Tech Vasc Interv Radiol. 2010, 13: 37-42. 10.1053\/j.tvir.2009.10.005.","journal-title":"Tech Vasc Interv Radiol"},{"key":"710_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1053\/j.semvascsurg.2010.05.001","volume":"23","author":"PH Lin","year":"2010","unstructured":"Lin PH, Weakley SM, Kougias P: How to interpret data from the superficial femoral artery stenting trials and registries. Semin Vasc Surg. 2010, 23: 138-47. 10.1053\/j.semvascsurg.2010.05.001.","journal-title":"Semin Vasc Surg"},{"issue":"2 Suppl 2","key":"710_CR6","first-page":"II63","volume":"16","author":"MW Mewissen","year":"2009","unstructured":"Mewissen MW: Primary nitinol stenting for femoro-popliteal disease. J Endovasc Ther. 2009, 16 (2 Suppl 2): II63-II81.","journal-title":"J Endovasc Ther"},{"issue":"Suppl 1","key":"710_CR7","first-page":"I147","volume":"16","author":"M Schillinger","year":"2009","unstructured":"Schillinger M, Minar E: Past, present and future of femoro-popliteal stenting. J Endovasc Ther. 2009, 16 (Suppl 1): I147-I152.","journal-title":"J Endovasc Ther"},{"key":"710_CR8","first-page":"783","volume":"51","author":"WM Fritschy","year":"2010","unstructured":"Fritschy WM, Kruse RR, Frakking TG, Van Geloven AA, Blomme AM: Performance of ePTFE-covered endograft in patients with occlusive disease of the superficial femoral artery: a three-year clinical follow-up study. J Cardiovasc Surg (Torino). 2010, 51: 783-90.","journal-title":"J Cardiovasc Surg (Torino)"},{"key":"710_CR9","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jvs.2010.03.071","volume":"52","author":"K McQuade","year":"2010","unstructured":"McQuade K, Gable D, Pearl G, Theune B, Black S: Four-year randomized prospective comparison of percutaneous ePTFE\/nitinol self-expanding stent graft versus prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. J Vasc Surg. 2010, 52: 584-90. 10.1016\/j.jvs.2010.03.071.","journal-title":"J Vasc Surg"},{"key":"710_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jvs.2006.08.074","volume":"45","author":"J Kedora","year":"2007","unstructured":"Kedora J, Hohmann S, Garrett W, Munschaur C, Theune B, Gable D: Randomized comparison of percutaneous Viabahn stent grafts vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral arterial occlusive disease. J Vasc Surg. 2007, 45: 10-16. 10.1016\/j.jvs.2006.08.074.","journal-title":"J Vasc Surg"},{"key":"710_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jvs.2008.08.041","volume":"49","author":"K McQuade","year":"2009","unstructured":"McQuade K, Gable D, Hohman S, Pearl G, Theune B: Randomized comparison of ePTFE\/nitinol self-expanding stent graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. J Vasc Surg. 2009, 49: 109-15. 10.1016\/j.jvs.2008.08.041.","journal-title":"J Vasc Surg"},{"key":"710_CR12","volume-title":"Eur J Vasc Endovasc Surg","author":"JS Lindholt","year":"2011","unstructured":"Lindholt JS, Gottschalksen B, Johannesen N, Dueholm D, Ravn H, Christensen ED, Viddal B, Fl\u00f8renes T, Pedersen G, Rasmussen M, Carstensen M, Gr\u00f8ndal N, Fasting H: The Scandinavian Propaten(\u00ae) Trial - 1-Year Patency of PTFE Vascular Prostheses with Heparin-Bonded Luminal Surfaces Compared to Ordinary Pure PTFE Vascular Prostheses - A Randomised Clinical Controlled Multi-centre Trial. Eur J Vasc Endovasc Surg. 2011,"},{"key":"710_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jvs.2005.10.037","volume":"43","author":"M Bosiers","year":"2006","unstructured":"Bosiers M, Deloose K, Verbist J, Schro\u00eb H, Lauwers G, Lansink W, Peeters P: Heparin-bonded expanded polytetrafluoroethylene vascular graft for femoro-popliteal and femorocrural bypass grafting: 1-year results. J Vasc Surg. 2006, 43: 313-8. 10.1016\/j.jvs.2005.10.037.","journal-title":"J Vasc Surg"},{"key":"710_CR14","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jvs.2009.12.042","volume":"51","author":"R Pulli","year":"2010","unstructured":"Pulli R, Dorigo W, Castelli P, Dorrucci V, Ferilli F, De Blasis G, Monaca V, Vecchiati E, Pratesi C, Propaten Italian Registry Group: Midterm results from a multicenter registry on the treatment of infrainguinal critical limb ischemia using a heparin-bonded ePTFE graft. J Vasc Surg. 2010, 51: 1167-77. 10.1016\/j.jvs.2009.12.042. e1","journal-title":"J Vasc Surg"},{"issue":"87","key":"710_CR15","doi-asserted-by":"publisher","first-page":"3D","DOI":"10.1016\/S0002-9149(01)01671-X","volume":"28","author":"FA Schmieder","year":"2001","unstructured":"Schmieder FA, Comerota AJ: Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. Am J Cardiol. 2001, 28 (87): 3D-13D.","journal-title":"Am J Cardiol"},{"key":"710_CR16","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.ejvs.2009.01.003","volume":"37","author":"M Lep\u00e4ntalo","year":"2009","unstructured":"Lep\u00e4ntalo M, Laurila K, Roth WD, Rossi P, Lavonen J, M\u00e4kinen K, Manninen H, Romsi P, Per\u00e4l\u00e4 J, Bergqvist D, Scandinavian Thrupass Study Group: PTFE bypass or thrupass for superficial femoral artery occlusion? A randomised controlled trial. Eur J Vasc Endovasc Surg. 2009, 37: 578-84. 10.1016\/j.ejvs.2009.01.003.","journal-title":"Eur J Vasc Endovasc Surg"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-12-178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1745-6215-12-178\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-12-178","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1745-6215-12-178.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T15:28:18Z","timestamp":1630510098000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/1745-6215-12-178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,18]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["710"],"URL":"https:\/\/doi.org\/10.1186\/1745-6215-12-178","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,18]]},"assertion":[{"value":"14 May 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"178"}}